Because HCC has a distinctive immunohistochemical (IHC) pattern, some IHC markers, such as Glypican-3 (GPC3), hepatocyte paraffin 1 (HepPar1), polyclonal CEA (pCEA), MOC-31, CD10, and α-fetoprotein (AFP), have been used to differentiate HCC from other tumors and to evaluate prognosis [4–18]. The gene discussed is MME; the disease is hepatocellular carcinoma.